Status:
UNKNOWN
Iron Profile in Patients With Congenital Cyanotic Heart Disease
Lead Sponsor:
Assiut University
Conditions:
Congenital; Cyanotic Heart Disease
Eligibility:
All Genders
1-18 years
Brief Summary
Iron is a vital substrate for hemoglobin production and sufficient iron stores are necessary to achieve and maintain adequate levels of hemoglobin.
Detailed Description
Iron is a vital substrate for hemoglobin production and sufficient iron stores are necessary to achieve and maintain adequate levels of hemoglobin. Unfortunately, more than one third of patients with ...
Eligibility Criteria
Inclusion
- \- 1. Age: 1month to 18 years 2. Pediatric patients attending and admitted to Assuit University Children Hospital and diagnosed to have congenital cyanotic heart disease evidenced by clinical picture and echocardiography.
- 3\. Both sexes.
Exclusion
- 1\. Patients with acyanotic congenital heart disease. 2. Patients who had surgical correction. 3. Patients who received iron supplements in previous three months. 4. Patients who have another systemic disease that affect iron profile and cause anemia as Chronic kidney disease or Hemolytic anemia
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04104061
Start Date
October 1 2019
End Date
October 1 2021
Last Update
September 26 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.